title: Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
abstract: Aim of this prospective study is to evaluate the effect of repaglinide t.i.d. (three times a day) plus single-dose insulin glargine regimen in low-risk type 2 diabetic patients during Ramadan fasting. Participants had been taking the regimen for at least 3 months. Patients with a history of diabetic coma, severe hypoglycemic crisis or repeating attacks of hypoglycemia were excluded. Hypoglycemic unawareness, kidney or liver disease or HbA1c over 8% were also accepted as exclusion criteria. Eleven patients who insisted on this worship and eight non-fasting cases were involved. All were told to make home-glucose-monitorisation weekly and report any hypoglycemic event throughout Ramadan. Fasting blood glucose (FBG), post-prandial blood glucose (PBG) and fructosamine levels, body weights and blood pressures were recorded just before and after Ramadan. Seven patients in each group concluded the follow-up. Any significant change was detected in the parameters in either groups (P>0.05). Glucose control remained unchanged; fructosamine 318.14+/-65.38 versus 317.28+/-52.80 mmol/L in fasting group, 290.71+/-38.48 versus 290+/-38.56 mmol/L in non-fasting group. None of them exhibited either a major or a minor hypoglycemic event. The results of this pilot study indicated that repaglinide t.i.d. plus single-dose insulin glargine regimen was safe for low-risk type 2 diabetic patients who insisted on fasting during Ramadan.
authors.affiliation: Division of Endocrinology and Metabolism, Baskent University Faculty of Medicine, 06490 Ankara, Turkey.
authors.forename: Okan
authors.initials: O
authors.lastname: Bakiner
authors.forename: Melek E
authors.initials: ME
authors.lastname: Ertorer
authors.forename: Emre
authors.initials: E
authors.lastname: Bozkirli
authors.forename: Neslihan B
authors.initials: NB
authors.lastname: Tutuncu
authors.forename: Nilgun G
authors.initials: NG
authors.lastname: Demirag
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D015190:Blood Glucose Self-Monitoring; D001794:Blood Pressure; D002219:Carbamates / Q000008:administration & dosage / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005215:Fasting / Q000502:physiology*; D005260:Female; D019270:Fructosamine / Q000097:blood; D006801:Humans; D007003:Hypoglycemia / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D007514:Islam; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D010880:Piperidines / Q000008:administration & dosage / Q000627:therapeutic use*; D018570:Risk Assessment; D012449:Safety; D014421:Turkey
chemical_list: D001786:Blood Glucose; D002219:Carbamates; D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D010880:Piperidines; D000069036:Insulin Glargine; D019270:Fructosamine; C072379:repaglinide